INTRODUCTION
Cancer chemotherapy had been to a large extent ineffective until the development of broad regimes combining different agents. The limited efficacy of monotherapy reflects tumor heterogeneousity and genetic instability, favouring escape of resistant tumor subpopulations. Cancer vaccination offers a different angle of attack, as compared to cytostatics, and may therefore be particularly effective in combinatory regimes. However, most chemotherapeutic agents are immunosuppressive, and it was long assumed that vaccines should therefore not be combined with chemotherapy. More recent knowledge has challenged this conventional wisdom (1, 2) . In particular, it is discussed whether chemotherapy may be utilized to counter tumor protection from regulatory T cells (Tregs), while prevailing the immunocompetence necessary for vaccine response (3) (4) (5) .
Here we report a proof-of-principle trial (phase I/II) of combined therapy with temozolomide and telomerase peptide vaccination in 25 stage IV melanoma patients. The primary objectives were toxicity and immunological response. Tumor response was a secondary study objective. Current prognosis for metastatic melanoma is dismal, with median survival of 4-9 months in patients with visceral involvement (6, 7) . Dacarbazine has been considered standard treatment, but the tumor response rate is only 6-15%, mostly partial responses, and there is no documented effect on survival (7) . The oral drug temozolomide is metabolized to dacarbazine in vivo and carries a potential advantage in penetration of the blood- Telomerase represents a possible target for universal cancer vaccines (10, 11) .
The enzyme maintains telomere length in dividing cells and is considered essential for tumor growth. Telomerase activity has been demonstrated in all studied cancer forms, including stem-cell like tumor cells (12) (13) (14) . Interesting results have been reported from phase I/II studies with three telomerase peptide vaccines (15) (16) (17) (18) (19) (20) .
Peptide GV1001 represents a 16 amino acid sequence from the active site of human telomerase reverse transcriptase (hTERT) (21, 22) .
The peptide was selected based on computer algorithms predicting strong HLA class II binding properties and multiple nested HLA-class I binding motifs. The GV1001 vaccine may thus recruit both CD4+ T-helper cells and CD8+ cytotoxic T cells. We have previously conducted two phase I/II trials with GV1001, in pancreatic and lung cancer patients (19, 20) . Both studies were conducted without chemotherapy. The results indicated no serious adverse effects, a GV1001-specific immune response in ~60% of patients and an association between immune response and survival. T cell clone studies demonstrated both T helper-and cytotoxic responses (19, 20, 23) . In the present trial, we hypothesized that temozolomide may enhance the immune response by inducing antigen release or modulating tumor tolerance. The study is to our knowledge the first clinical trial evaluating combinatory therapy with temozolomide and a cancer vaccine.
Research. 
Treatment
The treatment schedule is shown in Appendix Figure A1 
Clinical evaluation
Tumor response was assessed by CT scans and clinical examination at 12-week intervals, and classified according to the Response Evaluation Criteria in Solid Tumors (RECIST) (24) . Tumor response and survival was evaluated by intention-totreat analysis.
Research. Blood screening and assessment of adverse drug reactions were performed at each visit. Adverse events were graded according to the National Cancer Institute common toxicity criteria (NCI-CTC) version 3.0 and considered related to treatment if the relationship was reported as probable or suspected.
Immunological evaluation
PBMCs were obtained at weeks 0, 5, 9 and 12 and at every third booster vaccination. Pre-and post-vaccination samples were analyzed in parallel for proliferation response to GV1001 peptide stimulation ( 3 H-Thymidine assays). T cell responses were considered GV1001-specific when the stimulatory index (SI; response with antigen divided by response without antigen) was above 2. Specific immune responses were further characterised by cytokine assays and T cell clone experiments (HLA restriction, specificity for truncated peptides, response to recombinant hTERT protein). Materials and methods for immunological assays, DTH recording, flow cytometry and production of peptides and recombinant hTERT protein are described in Appendix 1.
Statistics
The study reports overall survival and progression free survival, calculated from start of study treatment. Overall survival for the intention-to-treat population, calculated using the Kaplan-Meier method, was compared with predicted survival based on a meta-analysis of clinical trials including 2100 patients (6) . The metaanalysis was conducted by Korn and co-workers for providing survival benchmarks
Research. for small scale trials. We performed the calculation as recommended (6) . Briefly, prognostic factors (sex, ECOG status, metastatic category) from our patients were inserted into a mathematical formula generating predicted survival. The calculation was based on trials where brain metastases were not excluded, because we did not perform screening for brain involvement (see Discussion). A 95% confidence interval was generated for survival of the study group (n=25), while the predicted survival curve was regarded as a fixed estimate (Fig 3) . Survival after one year for the study group was compared with predicted survival by use of Student's t-test.
RESULTS

Patient characteristics
Twenty-five patients with advanced stage IV melanoma were enrolled ( Table 1 ).
The majority (16/25) had M1C disease (visceral metastases or elevated LDH); the remaining nine patients had M1B disease (pulmonary metastases). Metastatic sites, age, sex and treatment details are listed in Appendix Table A1 .
Toxicity
The combined therapy with temozolomide and GV1001 was well tolerated. One grade III-IV toxicity was observed. Milder side effects were recorded in all patients, most commonly representing nausea, vomiting, fatigue or local skin reactions at the injection site. Allergic reactions (grade II) were observed in two subjects.
Finally, there was no evidence of long term toxicity in follow-up samples from patients with extended survival, in spite of durable GV1001-specific responses and repeated booster vaccination (maximum observation 5 years, see below).
Induction of immune responses
T cell proliferation assays were performed on pre-and post vaccination PBMCs from 23/25 patients, i.e. all patients where the relevant PBMCs were obtained. A GV1001-specific T cell response was demonstrated in 18/23 (78%) of patients after vaccination (Fig. 1A) . Six subjects had a GV1001-response prior to vaccination (Fig. 1A) , suggesting spontaneous priming against naturally expressed GV1001 or cross-reacting epitopes. The stimulatory index increased substantially after vaccination even in these six patients (2.1ĺ79 ; 3.2ĺ35 ; 4.6ĺ29 ; 7.5ĺ24 ; 11ĺ116 ; 26ĺ122). Among those developing de novo responses, 40% developed a response by week 5 and 90% by week 9.
The DTH-reactions were negative during standard study treatment in all subjects where recordings were obtained, including 11 immune responders in T cell assays.
Interestingly, three patients turned positive after omission of temozolomide and continuous booster vaccination. In our previous GV1001 trials without temozolomide (19, 20) , the DTH reactions were positive in a substantial number of 
Development of long term T cell memory
Most cancer vaccine trials have for practical reasons been limited to short term vaccination and immuno-monitoring, while clinical efficacy probably requires long term T cell responses (25, 26) . Here, immune responders were offered continued monthly vaccination. Long term follow-up revealed that 10/12 patients continuing vaccination developed durable GV1001-specific T cell activity. Strikingly, the 10 patients with durable T cell responses at month 6 all survived longer than the two patients rapidly losing their responses (Table 1) . Moreover, the survivors exhibited retained responses in follow-up samples obtained at later time points, ranging from week 36 to week 258 (Fig. 1B , Table 1 and data not shown).
Tumor response
All 25 patients enrolled had progressive disease at study entry and belonged to the most advanced categories within stage IV (64% M1C; 36 % M1B; 0% M1A).
Interestingly, five subjects developed partial tumor regression (PR). Their tumor volumes decreased by 65-96% (Fig 2A) . An additional six patients experienced disease stabilization, while 14 subjects had continued progressive disease (PD).
All five patients with PR developed GV1001-specific T cell responses, and the immune responses prevailed throughout their tumor regression periods (Fig 1B) .
Interestingly, the clinical responses developed far more gradually than expected from chemotherapy, with only one reaching PR at week 12, three more within week 36 and the fifth at week 48.
Patient 19 (P19) had disseminated MIC melanoma at study entry, including multiple visceral metastases. After start of vaccination, no new lesions appeared.
The total tumor diameter started gradually decreasing, reached PR at week 48 and has continued to regress over a period exceeding 5 years (Fig 2B) . Remarkably, the patient has no symptoms of tumor disease, and all residual CT-lesions are negative on FDG-PET scans. As melanomas are highly PET-sensitive, the patient may have a complete response. She currently receives booster vaccines at 3-month intervals and retains a strong GV1001-specific immune response (Fig 1B) .
Patient 11 (P11) had multiple metastases to lung and mammary glands at study entry. CT-evaluations demonstrated a 29% regression in total tumor diameter at week 12, improving to 74% at week 36. All five metastases regressed partly or completely (Fig 2A and Appendix Fig A3) . We recorded PD at week 84 due to a new subcutaneous lesion, but continued vaccination and temozolomide. The 
2A). CT scans demonstrated regression of 6/8, 4/4 and 7/7 pre-study lesions, respectively (Fig 2A and Appendix Figs A2, A3 ). versus 84 days). These differences did not reach statistical significance (log rank test; p>0.05), reflecting the low number of subjects. Advanced melanoma patients usually progress further within weeks or few months (6, 8) . It is therefore of interest that the five PR patients exhibited extended PFS ranging from 8 to >62 months, as well as OS ranging from 19 to >62 months.
Progression-free and overall survival
Trial subjects may differ from other patients, e.g. due to selection processes determining which individuals are referred to trial units. Korn et al have conducted a meta-analysis of 2100 trial patients and suggested that survival in phase I/II melanoma studies is compared with their data set (6) . They also outlined a method for calculating predicted survival, correcting for prognostic factors. Applying this method, we calculated a survival advantage for the present study treatment, bordering 95% statistical significance ( Fig. 3; intention-to-treat analysis) 
apparent advantage was relatively stable at different time points (one year: 44% versus 24%, two years: 16% versus 6.6%, three years: 12% versus 3.7%).
Moreover, one may note that the "control group" was not based on untreated subjects, but on trial patients receiving potentially active therapy. Korn et al suggested declaring a treatment worthy of further study if the one-year survival was better than predicted, with a p value less than 0.10. This criterion was met both by intention-to-treat and per protocol analysis (p=0.059 and p=0.032, respectively). The interpretation of these findings is still complex, as discussed below.
T cell clones from clinical responders
We generated eight GV1001-specific T cell clones from two clinical responders (P11 and P22). The clones were HLA class II DR restricted (Fig. 4A and data not shown). Taken together with our data from other studies ((19, 23) and unpublished), we find that GV1001 is recognised on a series of DP, DR and DQ molecules. The HLA-promiscuousity of GV1001 suggests that the vaccine is applicable to the general patient population, without a need for HLA-typing.
A diverse response in terms of HLA-restriction and fine-specificity may reduce the risk of tumor escape (25) . Here, we determined the fine-specificity of T cell clones by experiments with truncated peptides spanning the GV1001 aa-sequence. The four analyzed clones from subject P22 recognised three different core motifs from the N-terminal part of GV1001 (Fig. 4B) . One of the motifs was shared by a P11 clone (Fig. 4D) . In previous studies, we have observed that multiple motifs from the central and C-terminal parts of peptide GV1001 may also be recognised (21) .
Vaccine-specific T cell clones may be of sparse relevance in vivo if they fail to recognize naturally processed antigens. Here, we observed recognition of naturally processed hTERT epitopes (Fig. 4C,D) . Most clones responded more vigorously to hTERT protein than to pure GV1001 peptide (Fig 4C and data not shown) . We also noted strong responses against low concentrations of truncated peptides (Fig.   4C,D) . These observations suggest that the clones may have higher affinity for naturally processed epitopes than for the vaccine peptide. The data also point to a simple mechanism for epitope spreading, as the cross-reacting natural epitopes may stretch beyond the GV1001-sequence.
Cytokine profiles
The cytokine profiles for 14/18 immunological responders were investigated in Bioplex assays by use of panels measuring up to 27 cytokines. The results demonstrated GV1001-specific secretion of multiple cytokines in all 14 patients (Fig 5 and Appendix Table A2 ). According to the Th1/Th2-paradigm, a Th1-like pattern is desirable for cancer eradication (27) . However, we have previously observed that human responses frequently do not to follow a Th1/Th2-delineation (23, 28, 29) . The present responses comprised high levels of key Th1-cytokines IFNγ and TNFα, but also of hallmark Th2-cytokines IL-5 and IL-13. This applied both to the T cell bulk cultures (Fig 5) and to the T cell clones [(23) and data not shown]. Collectively, our present and previous results indicate that cytokine profiling should not rely on a Th1/Th2-dichotomy. Of note, we detected only low levels of IL-4 and IL-10 (Fig 5) . The responses would therefore easily be designated "Th1" with commonly used panels measuring only IFNγ, TNFα, IL4
and/or IL-10. Interestingly, the high IFNγ/IL-10 ratios may reflect a favourable balance between immunity and tolerance, as IL-10 is considered to promote regulatory T cells and "tolerogenic" dendritic cells.
The analyses further demonstrated GV1001-specific secretion of a broad range of pro-inflammatory cytokines and chemokines (Appendix Table A2 ), including IL-1β, IL-6, IL-8, GM-CSF and MIP-1β. This polyfunctional cytokine profile was observed in all evaluated patients, both in T cell bulk cultures and T cell clones [Appendix Table A2 , (23) and data not shown]. We also noted that the GV1001-specific responses included IL-17. A subset of activated T cell clones may thus belong to the Th17-lineage (30, 31) .
Finally, we asked whether temozolomide had affected the cytokine profile of the GV1001 response and compared the cytokine patterns to data from patients in our other GV1001 trials (Appendix Figure A4, (20, 23) 
DISCUSSION
The concept of combining cancer vaccination with chemotherapy is attractive, but also challenging. Due to the long-standing assumption that chemotherapy would preclude immunization, there is sparse experience on how these modalities interact. Here, we combined temozolomide with an hTERT peptide vaccine. The lack of increased toxicity is of particular interest as temozolomide is bone marrow toxic and telomerase is expressed by haematological stem cells. There is also no evidence of long term toxicity in subjects receiving up to 5 years booster vaccination, in spite of durable immune responses. Interestingly, the immunological response rate of 78% is higher than in any previous GV1001 trial (19) (20) (21) (22) 32) . The present GV1001-responders developed polyfunctional cytokine profiles with mixed Th1/Th2-patterns and a high IFNγ/IL-10 ratio (Fig 5 and Appendix Table A2 ).
The broad and pro-inflammatory cytokine profile may mobilize the adaptive and the innate immune system. Interestingly, polyfunctional cytokine profiles have been associated with protective immunity in patients surviving HIV or Leishmania (46) (47) (48) . Polyfunctional cytokine patterns may be particularly important in a cancer vaccine setting, where there is a need to overcome established tumor tolerance and transform the inflammatory milieu. 
Six patients in the present trial harboured T cell responses against GV1001 prior to vaccination, and others have reported spontaneous GV1001-specific activity in subjects with chronic lymphocytic leukaemia (49) . Further, we demonstrate that GV1001-specific T cell clones recognize endogenous APCs pulsed with hTERT protein. Both the pre-vaccination reactivity and the hTERT protein responses suggest that GV1001-associated epitopes are naturally processed and immunogenic in cancer patients. The present study did not include screening of tumors for telomerase expression and hence did not address whether quantitative differences in expression level between patients may have influenced the vaccine response.
We report objective tumor regression in 5 patients and temporary disease stabilisation in an additional 6 subjects. Several observations suggest that the regressions are unlikely to be caused only by temozolomide. First, all clinical responders belonged to the immunological response group and developed long term GV1001-specific memory. Second, the response rate is relatively high compared to the ~13% rate reported in phase III temozolomide trials (8, 50) . Third, chemotherapy responses rarely occur in patients like P19 with widespread visceral metastases outside of lung. Fourth, P19 developed most of her tumor regression after omitting temozolomide at month 8 and continuing vaccination (Fig. 2B) . survival from a possibly earlier point ("time of registration"). The latter difference suggests that our survival advantage may be underestimated. In all, these issues illustrate that any comparison between different trials carries considerable uncertainty. The apparent survival benefit of GV1001/temozolomide is interesting, but need to be reproduced with a randomized control group.
We conclude that combined therapy with temozolomide and GV1001 is well 
